$1.20
2.75%
Nasdaq, Fri, Nov 15 2024
ISIN
US62856X1028
Symbol
MYMD

MyMD Pharmaceuticals Inc Stock price

$1.20
-0.60 33.58% 1M
-0.90 43.07% 6M
-6.57 84.59% YTD
-9.31 88.62% 1Y
-269.40 99.56% 3Y
-420.17 99.72% 5Y
-31,448.40 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.03 2.75%
ISIN
US62856X1028
Symbol
MYMD
Sector

Key metrics

Market capitalization $3.29m
Enterprise Value $-9.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.96
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-13.40m
Free Cash Flow (TTM) Free Cash Flow $-9.67m
Cash position $13.07m
EPS (TTM) EPS $-10.69
Short interest 14.70%
Show more

Is MyMD Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

MyMD Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:

Buy
100%

Financial data from MyMD Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.92 6.92
20% 20%
-
- Research and Development Expense 6.47 6.47
11% 11%
-
-13 -13
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
16% 16%
-
Net Profit -18 -18
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about MyMD Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MyMD Pharmaceuticals Inc Stock News

Neutral
Business Wire
4 months ago
BALTIMORE--(BUSINESS WIRE)---- $MYMD--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker...
Neutral
Business Wire
4 months ago
BALTIMORE--(BUSINESS WIRE)---- $MYMD--TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name “TNF Pharmaceuticals, Inc.,” effective today. The Company's common ...
Neutral
Business Wire
5 months ago
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced the appointment of Mitchell Glass, M.D., a member of the board of directors of the Company, as president and chief medical...
More MyMD Pharmaceuticals Inc News

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical stage pharmaceutical company which engages in extending healthy lifespan. It involves in developing and commercializing therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. The company is headquartered in Baltimore, MD.

Head office United States
CEO Christopher Chapman
Employees 6
Founded 1989
Website tnfpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today